← board
ETST
distress 2/10 · well-funded / low risk$0.15+7%today-37% from 52w high
Revenue
$36M
Liquidity
$1M
Runway
—
Shares 1y
-2%
Price & events
+1.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+7.1%
1D
-11.1%
1W
-15.6%
1M
+3.4%
3M
+1.4%
6M
-25.0%
1Y
-33.3%
2Y
+689.5%
5Y
+476.9%
All
Overview
- Market Cap
- $43.23M
- Enterprise Value
- $42.47M
- Volume
- 11.55K
- 52 Week Range
- $0.08 – $0.24
- Total Shares
- 288.17M
- Float Shares
- 89.26M
- % Held by Insiders
- 66.70%
- % Held by Institutions
- 0.00%
- RVOL
- 0.22x
- Beta
- 2.41
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-01-05partnershipEngaged Hayden IR to support investor outreach and communications strategy.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $1 (+567% upside) · 1 analysts
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.